Skip to main content
SpringerLink
Log in

Virtuelle Prostatektomie mit einer ultrahoch dosierten Single-dose-Strahlentherapie

Virtual prostatectomy using single dose radiotherapy

  • Literatur kommentiert
  • Published:
Strahlentherapie und Onkologie Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Brand DH, Tree AC, Ostler P et al (2019) Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 20(11):1531–1543. https://doi.org/10.1016/S1470-2045(19)30569-8

    Article  PubMed  PubMed Central  Google Scholar 

  2. Zilli T, Franzese C, Bottero M et al (2019) Single fraction urethra-sparing prostate cancer SBRT: phase I results of the ONE SHOT trial. Radiother Oncol 139:83–86. https://doi.org/10.1016/j.radonc.2019.07.018

    Article  PubMed  Google Scholar 

  3. Morton G, Mcguffin M, Chung HT et al (2020) Prostate high dose-rate brachytherapy as monotherapy for low and intermediate risk prostate cancer: efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy. Radiother Oncol 146:90–96. https://doi.org/10.1016/j.radonc.2020.02.009

    Article  CAS  PubMed  Google Scholar 

  4. Gomez-iturriaga A, Buchser D, Mayrata E et al (2020) Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial. Radiother Oncol 146:16–20. https://doi.org/10.1016/j.radonc.2020.01.025

    Article  CAS  PubMed  Google Scholar 

  5. Dearnaley D, Syndikus I, Mossop H et al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5‑year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17(8):1047–1060. https://doi.org/10.1016/S1470-2045(16)30102-4

    Article  PubMed  PubMed Central  Google Scholar 

  6. Tharmalingam H, Tsang Y, Ostler P, Wylie J, Bahl A, Lydon A (2020) Single dose high-dose rate (HDR) brachytherapy (BT) as monotherapy for localised prostate cancer: early results of a UK national cohort study. Radiother Oncol 143:95–100. https://doi.org/10.1016/j.radonc.2019.12.017

    Article  PubMed  Google Scholar 

  7. Crook JM, Tang C, Thames H et al (2020) A biochemical definition of cure after brachytherapy for prostate cancer. Radiother Oncol 149:64–69. https://doi.org/10.1016/j.radonc.2020.04.038

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Hamdy FC, Donovan JL, Lane JA et al (2016) 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 375:1415–1424. https://doi.org/10.1056/NEJMoa1606220

    Article  PubMed  Google Scholar 

  9. Donovan JL, Hamdy FC, Lane JA et al (2016) Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate. Cancer. https://doi.org/10.1056/NEJMoa1606221

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Bern University, Inselspital, Freiburgstraße 10, 3010, Bern, Schweiz

    Mohamed Shelan,  Elena Riggenbach &  Daniel M. Aebersold

Authors
  1. Mohamed Shelan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elena Riggenbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel M. Aebersold
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohamed Shelan.

Ethics declarations

Interessenkonflikt

M. Shelan, E. Riggenbach und D. M. Aebersold geben an, dass kein Interessenkonflikt besteht.

Additional information

Originalpublikation

Greco C et al (2021) Safety and efficacy of virtual prostatectomy with single-dose radiotherapy in patients with intermediate-risk prostate cancer: results from the PROSINT phase II randomized clinical trial. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2021.0039

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shelan, M., Riggenbach, E. & Aebersold, D.M. Virtuelle Prostatektomie mit einer ultrahoch dosierten Single-dose-Strahlentherapie. Strahlenther Onkol 197, 943–945 (2021). https://doi.org/10.1007/s00066-021-01824-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00066-021-01824-y

Search

Navigation